Effect of tranexamic acid on symptomatic venous thromboembolism in patients undergoing primary total knee arthroplasty.

INTRODUCTION: This study aimed to investigate the effect of tranexamic acid (TXA) with sequential routine anticoagulation on postoperative symptomatic venous thromboembolism (VTE) in patients undergoing primary total knee arthroplasty (TKA).
MATERIAL AND METHODS: This was a prospective study with randomized trials. From January 2013 to May 2015, 1880 patients undergoing primary TKA were enrolled in this study. Seven hundred and twenty patients who received TXA injection were included in the TXA group while 1160 patients who received placebo injection were included in the control group. Patients in the TXA group were treated with intravenous TXA or topical intravenous TXA, and all received sequential routine anticoagulation 12 h after the operation. We extracted data of patients' sex, age, primary diagnoses, and comorbidities that could potentially affect the prevalence rate of VTE. To discuss the risk factors of symbolic VTE, comparisons were made within the TXA group between patients with symbolic VTE and non-symbolic VTE. Logistic regression analysis was performed to analyze the concurrent effects of various factors on the prevalence rate of postoperative VTE.
RESULTS: Thigh perimeter was not closely associated with TXA injection. Within the TXA group, 24 (3.3%) patients had perioperative symptomatic VTE, 16 (2.2%) deep vein thrombosis (DVT) and 8 (1.1%) pulmonary embolism. High body mass index (BMI), low fibrinogen (Fbg) and simultaneous bilateral TKA were significant risk factors in both univariate analysis and multivariate analysis.
CONCLUSIONS: Increased BMI, low Fbg, and simultaneous bilateral TKA could act as risk factors for postoperative symptomatic VTE treated with TXA. Copyright:

Introduction

Total knee arthroplasty (TKA), one of the most common curative operations for end-stage arthritis of the knee, can effectively relieve pain, improve the knee function, and improve the quality of patients’ life [1-3]. In the United States, there are over 600,000 TKAs and over 285,000 total hip arthroplasties (THAs) performed every year [4]. The demand for primary TKA is predicted to grow by 673%, to reach 3.48 million by 2030 in the United States. Although the operation has good outcomes and is generally well tolerated, the complications of blood transfusion are also severe, including infection, transfusion-related liver damage, hemolysis, immune suppression, prolonged rehabilitation duration and allergic reactions [5], and blood loss is a major concern both during and after TKA surgery [6].

In western countries, venous thromboembolism (VTE) is composed of pulmonary embolism (PE) and deep venous thrombosis (DVT), and it has been identified as a significant public health concern [7, 8]. Undergoing THA and TKA could significantly increase the risk of VTE, whose prevalence rate was estimated as 60% without appropriate prophylaxis [9]. Venous thromboembolism is also a major contributor to morbidity and mortality among orthopedic patients and body mass index (BMI) could be correlated with it [8]. Mortality rates from VTE following lower limb arthroplasty are low. It was estimated that before 1980, the VTE prevalence rate without prophylaxis was about 15–30%, but it has been reduced to 1–2% after the contemporary prophylactic strategies were applied in 2001 [10]. Now, even though the administered drug remained controversial, the western guidelines have strongly recommended routine chemoprophylaxis to reduce the incidence of VTE for patients who underwent TKA [11].

Tranexamic acid (TXA) is an analog of lysine that can reduce blood transfusion and loss, and it can efficiently inhibit fibrinolysis through hindering plasmin’s binding to fibrin and activation of plasminogen [2, 12, 13]. Tranexamic acid has been applied widely in cardiac surgery, tonsillectomy, spinal surgery, hemophilia, gynecological surgery and oral surgery [14]. It has also been shown that TXA can significantly reduce blood loss and transfusion rates after TKA without increasing the incidence of VTE [15]. As reported by recent meta-analyses, the effect of intravenous (IV) TXA on blood loss was estimated to be up to around 600 ml for TKA [16-18]. Tranexamic acid (TXA) elicits an anti-fibrinolytic effect; in theory, TXA can be used to reduce blood loss in TKA. European and U.S. studies on this topic have shown that the intravenous administration of TXA can significantly reduce post-operative blood loss and the need for transfusion. However, limited information has been presented regarding the effectiveness and safety of TXA for Chinese patients subjected to TKA [19].

Although IV TXA has been well proved to be safe for healthy people, it was still unclear if this held true for patients with a history of VTE. It has been discredited that TXA acts as a procoagulant, and it had antithrombotic effects [20]. However, whether TXA had positive effects on VTE after TKA was still not well-defined, which was restricted by the small sample size. Thus, our study was designed to explore the effects of using TXA after first TKA surgery on the incidence rates of VTE, and analyze risk factors that affect the incidence of symptomatic VTE.

Material and methods

Patients’ characteristics

Prior to this trial, approval from the Institutional Ethics Committee of Peking Union Medical College Hospital was obtained. Additionally, written informed consent and research authorizations were obtained prospectively prior to surgery. From January 2013 to May 2015, multiple TKA cases involving 1880 patients were included in this study and randomized to the experimental group and control group. Inclusion criteria: (i) all the patients were undergoing primary TKA; (ii) the patients were over 18 years old; (iii) patients who received TXA injection were in the perioperative period; (iv) patients underwent a standardized VTE prophylactic anticoagulant therapy postoperatively; (v) all patients included had given written consent. Exclusion criteria: (i) patients had a history of venous thromboembolism, pulmonary embolism and coronary heart disease; (ii) patients had coagulopathy; (iii) oral non-steroidal anti-inflammatory drugs (NSAIDs) were discontinued for less than 1 week; (iv) patients were clearly allergic to TXA; (v) patients had severe liver and kidney dysfunctions; (vi) patients had high risk of thrombosis. In the end, a total of 720 cases (878 knees) were included in the TXA group, including 562 unilateral TKA cases and 158 bilateral TKA cases. Among them, there were 658 cases with primary osteoarthritis and 53 cases with rheumatoid arthritis.

Operation

Procedures were completed by four senior orthopedic surgeons for objectivity and reliability of experiments in this randomized comparison study (RCT). Patients randomized to the experimental group used TXA injection while those in the control group received placebo injection. The surgical techniques and procedures applied were up to date. Prophylactic intravenous antibiotics were given to all patients 30 min before the surgery. During the operation, medial parapatellar arthrotomy as the standard approach of exposure of the knee joint allowed adequate exposure for TKA. Then, anterior midline incision, the most commonly used skin incision for primary TKA, and a utilitarian extensile approach to the knee were done with the knee in flexion to allow the subcutaneous tissue to fall medially and laterally, improving exposure and obviating the need for raising skin flaps [21]. After the surgery, all patients used the posterior stabilized prosthesis and were fixed with bone cement. The tourniquet was not released until skin closure. A 16 gauge drainage tube was placed, and was opened after 3 to 4 h of postoperative clamping. Residual volume of the tube was less than 200 ml within 24 h, so the catheter/tube was then removed [22].

Evaluation and diagnosis of venous thromboembolism

Deep vein thrombosis was assessed before performing TKA. Patients were assessed with the Wells score to determine whether there was obvious swelling of the lower limbs (greater than the preoperative value of 3 cm), pain or Homan positiveness and usage of Doppler ultrasonography for investigating DVT. Variate scores indicate different probability of DVT diagnosis. A score < 2.0 means low probability, 2.0–6.0 means mediate probability, while > 6.0 indicates high probability. Diagnostic criteria: (i) venous lumen could not be closed; (ii) the cavity was hypoechoic or echoless; (iii) there was no or only a small amount of blood flow signal within venous thrombosis; (iv) the pulse of Doppler showed no blood flow or the spectrum did not change with respiration. If chest pain and chest tightness occur, patients should be immediately tested for pulmonary embolism with a CT pulmonary angiogram (CTPA).

Basic precautions

The process of TKA should be gentle and delicate to avoid intravenous intimal injury. The limb was raised to prevent deep venous reflux disorder or blood would not successfully flow around the body. Patients were encouraged to stand up, to perform early functional exercise, to get out of bed, to take deep breaths and to cough. The patients were suggested to drink more water, so that dehydration could be avoided.

Physical and drug prophylactic anticoagulation

An intermittent pneumatic foot vein pump and stretch socks were used. The patients were subcutaneously given enoxaparin sodium (Clexane, Sanofi Aventis) or orally given rivaroxaban (Xarelto, Bayer). In the first stage, enoxaparin sodium was given once a day, and the dosage was adjusted according to the patients’ weight. Some of the patients were subcutaneously given conventional doses (i.e. low-molecular-weight heparin) 12–24 h after TKA surgery (2–4 h after epidural catheter removal), and some were given half of the conventional doses 4–6 h after surgery, and the next day conventional doses were given. This process was generally repeated once every 24 h for 3–5 days. In the second stage, subcutaneous injection of low molecular weight heparin or oral administration of warfarin 10 mg once a day was used for 10–14 days after surgery.

Methods of using tranexamic acid

The use of TXA was mainly divided into two types: (i) 15 mg/kg TXA was intravenously injected in 15 min before release of the tourniquet; (ii) 15 mg/kg TXA with 1 g/50 ml TXA topical application was intravenously injected before tourniquet release.

Risk factors of symptomatic venous thromboembolism

The risk factors were selected based on the following: (i) relevant factors in the literature report; (ii) experience and accumulation in clinical work; (iii) factors that may be relevant but pending confirmation; (iv) indicators that were relatively independent, or may have certain relevance, but without a direct causal relationship. Thus, patients’ related factors were applied, including gender, age, BMI, diagnosis, personal history (i.e. history of smoking and alcohol consumption), comorbidities (i.e. hypertension, diabetes, cerebrovascular disease, malignancy history, arrhythmia) and American Anesthesiologists Association (ASA) score; patients classified as III and above are considered not qualified for an anesthesia. Preoperative laboratory tests were reviewed, including hematocrit (Hct), hemoglobin (Hgb), platelet count (Plt), prothrombin time (PT), international normalized ratio (INR), activated partial thrombin time (APTT), fibrinogen (Fbg) and D-dimer. Preoperative medication history was recorded, including aspirin and lipid-lowering agents. Operation-related factors were also described, including the surgeons (i.e. A, B, C, D), anesthesia, surgery (i.e. unilateral TKA and one-stage bilateral TKA), usage of tourniquet, and placement of drainage after operation.

Statistical analysis

All indicators were analyzed with SPSS 21.0 software (IBM, USA). Count data were presented as percentages, and measurement data were presented as mean and standard deviation. The risk factors for symptomatic VTE were analyzed by single factor analysis (i.e. χ2 test and independent sample t-test) and the multivariate logistic regression test. P < 0.05 was considered to indicate statistical significance.

Results

Basic information of included patients

A total of 1880 TKA patients were recruited; 720 of them received TXA injection while 1160 received placebo sodium chloride injection. There were significant differences in symptomatic VTE, indicating the effectiveness of TKA (Table I). No close association between thigh perimeter and TXA was found (p > 0.05, Figure 1). Tranexamic acid was found to be associated with adverse effects (Table II), which would possibly reduce the blood transfusion and blood loss. A total of 24 patients were found with symptomatic VTE, including 16 (2.2%) patients of symptomatic DVT and 8 (1.11%) cases of symptomatic PE. No deaths occurred 30 days after operation.

Table I

Baseline characteristics of subjects treated with traditional schemes and tranexamic acid

Indicators	Controls	Tranexamic acid	χ2/t	P-value
Number	1160	720
Age, mean ± SD [years]	68.4 ±8.93	66.47 ±7.64	0.168	0.868
Gender, n (%):
Male	184 (15.86)	176 (24.44)	21.360	< 0.001*
Female	976 (84.14)	544 (75.56)
BMI [kg/m2]:	26.92 ±3.84	26.74 ±4.08	−0.431	0.852
BMI < 25	431 (37.16)	253 (35.14)	0.780	0.502
BMI ≥ 25	729 (62.84)	467 (64.86)
Protopathy, n (%):
Osteoarthritis		658 (91.39)
Rheumatoid arthritis		53 (7.36)
Others		9 (1.25)
Diagnosis, n (%):
OA	1067 (91.98)	658 (91.39)	0.207	0.667
Non-OA	93 (8.02)	62 (8.61)
Surgery, n (%):
Unilateral TKA	817 (70.43)	562 (78.06)	13.312	< 0.001*
Bilateral TKA	343 (29.57)	158 (21.94)
Symptomatic VTE, n (%):
Yes	39 (3.36)	24 (3.33)	0.001	1.000
No	1121 (96.94)	696 (96.67)
PE, n (%):
Yes	2 (0.17)	6 (0.83)	3.150	0.170
No	1158 (99.83)	714 (99.17)
Near-end DVT, n (%):
Yes	6 (0.51)	6 (0.83)	0.290	0.821
No	1154 (99.49)	714 (99.17)

BMI – body mass index, OA – osteoarthritis, TKA – total knee arthroplasty, VTE – venous thromboembolism, PE – pulmonary embolism, DVT – deep vein thrombosis.

Figure 1

Comparison between tranexamic acid group and control group regarding thigh perimeter

Table II

Indicators related to peri-operative blood of subjects treated with traditional schemes and tranexamic acid

Indicators	Controls	Tranexamic acid	χ2/t	P-value
Number	1160	720
Peri-operative blood transfusion, n:
Unilateral	312/817	253/562	2.666	0.103
Bilateral	343/343	158/158	0	1
Total	655	411	0.019	0.89
Total peri-operative blood loss, mean ± SD [ml]:
Unilateral	1064 ±78.7	992 ±68.2	20.27	< 0.001
Bilateral	1682 ±63.5	1564 ±93.6	32.54	< 0.001
Peri-operative hidden blood loss, mean ± SD [ml]:
Unilateral	523 ±78.4	505 ±62.8	5.21	< 0.001
Bilateral	765 ±86.0	862 ±75.6	24.88	< 0.001

Analysis of risk factors in patients with symptomatic venous thromboembolism

Among 720 patients who received TXA, 24 had symptomatic VTE and 696 had other symptoms. Tables III–VI show the results of univariate analysis of perioperative TKA. The results show that BMI, Fbg, and surgical approach (i.e. unilateral TKA/a bilateral TKA) were significantly associated with symptomatic VTE (p < 0.05). On the other hand, diagnosis, personal history of smoking and alcohol, comorbidities (i.e. hypertension, diabetes, cerebrovascular disease, arrhythmia and hyperlipidemia), the number of complications, ASA score, preoperative test (i.e. hemoglobin, platelet, D-dimer, INR, PT, APTT), surgeons, anesthesia, drainage tube clamped or not, and the use of hemostatic zone showed no significant difference. Then, BMI (OR = 0.213, 95% CI: 0.017–0.635, p = 0.006), Fbg (OR = 2.550, 95% CI: 1.803–6.003, p = 0.032) and surgical type (OR = 3.612, 95% CI: 1.551–8.410, p = 0.003) were analyzed by a multivariate logistic regression model, indicating that they still showed significant correlations with symptomatic VTE (Table VII). The risk of VTE in bilateral surgery was 3.612 times higher than that in the unilateral operation, and increasing Fbg would result in a 2.55-fold increase in the risk of VTE (Table VII).

Table III

Univariate analysis of baseline characteristics between venous thromboembolism (VTE) and non-VTE patients

Indicators	TXA				Placebo
	Symptomatic VTE	Non-VTE	χ2/t	P-value	Symptomatic VTE	Non-VTE	χ2/t	P-value
Number	24	696			39	1121
Age, mean ± SD [years]:	66.74 ±7.694	66.46 ±8.937	0.146	0.884	68.71 ±9.151	68.37 ±8.454	0.229	0.821
< 60	7	131	2.245	0.325	7	184	0.798	0.671
60–79	17	542			27	836
≥ 80	0	23			5	101
Gender, n:
Male	9	166	2.305	0.129	10	174	2.892	0.140
Female	15	530			29	947
Mean BMI [kg/m2]:	26.75 ±3.80	26.08 ±4.08	0.793	0.428	27.19 ±3.62	26.23 ±3.97	1.489	0.137
BMI < 25	4	249	2.926	0.044	9	422	2.830	0.046
BMI ≥ 25	20	447			30	699
Diagnosis, n:
OA	22	636	0.132	0.717	36	1031	0.051	0.823
Non-OA	2	60			3	90
Smoking history, n:
Yes	3	85	0.075	0.783	6	134	0.769	0.380
No	21	611			33	987
Drinking history, n:
Yes	2	56	0.109	0.741	11	188	2.709	0.100
No	22	640			28	933
ASA rating, n:
1–2	22	645	0.025	0.876	34	999	0.014	0.904
3	2	51			5	122

BMI – body mass index, OA – osteoarthritis, ASA – American Society of Anesthesiologists, TXA – tranexamic acid.

Table VI

Univariate analysis of surgery-related parameters between venous thromboembolism (VTE) and non-VTE patients

Indicators	TXA				Placebo
	Symptomatic VTE	Non-VTE	χ2/t	P-value	Symptomatic VTE	Non-VTE	χ2/t	P-value
Number	24	696			39	1121
Anesthesia, n:
GA	19	588	0.175	0.675	35	924	0.944	0.331
Non-GA	5	108			4	197
Surgery, n:
Unilateral TKA	14	550	4.696	0.030	19	754	5.025	0.025
Bilateral TKA	10	146			20	367
Drainage, n:
Yes	22	686	3.182	0.074	36	1088	1.468	0.226
No	2	10			3	33
Surgeon, n:
A	6	243	5.176	0.16	6	243	6.318	0.097
B	12	215			12	215
C	3	180			3	180
D	3	58			3	58

TKA – total knee arthroplasty, GA – general anesthesia, TXA – tranexamic acid.

Table VII

Multi-variate analysis of parameters between venous thromboembolism (VTE) and non-VTE patients

Indicators	B	S.E.	Wald	df	OR	95%CI		P-value
						LL	UL
Surgery	1.284	0.431	8.864	1	3.612	1.551	8.41	0.003
BMI	−1.548	0.558	7.686	1	0.213	0.071	0.635	0.006
Fbg	0.936	0.437	4.59	1	2.55	1.803	6.003	0.032

BMI – body mass index, Fbg – fibrinogen, OR – odds ratio, LL – lower limit, UL – upper limit.

Intervention and outcome of symptomatic venous thromboembolism patients

All symptomatic VTE patients recovered. After definite diagnosis, low-molecular-weight heparin was subcutaneously injected from once a day to 2 times a day. After taking warfarin anticoagulation, patients were discharged as outpatients. The INR of prothrombin time for outpatient follow-up monitoring was maintained as 2–3 for 3 months. Dosage injection changed with different symptoms. Six PE patients were found without lower-limb swelling, pain symptoms or difficulty to correct hypoxemia. Thus, the dosage of low-molecular-weight heparin was changed from prevention to treatment, and oral warfarin anticoagulation was stopped and the patients discharged 2 weeks later. The INR of prothrombin time in outpatient follow-up monitoring was maintained as 2–3 for 3 months. No death occurred within 90 days after the operation.

Discussion

In order to decrease the risk of perioperative blood loss and transfusion, TXA has been extensively studied as an adjunct treatment for TKA [20]. However, TKA was one of the most highly risky procedures that would result in VTE [20, 23]. Hence, we sought to determine whether the usage of TXA was associated with increased risk of VTE.

There have been a variety of studies that reported the risk of VTE after TKA. Bin Abd Razak et al. [24] reported that in 531 Asian patients who underwent unilateral TKAs without drug anticoagulation after surgery, only 4 (0.75%) of them had symptomatic VTE, and 1 had symptomatic PE. However, in the meta-analysis by Januel et al., 44,844 cases of THA or TKA were included in 47 randomized clinical controls and observational studies [25]. All the subjects received anticoagulation to prevent VTE, showing that the total incidences of symptomatic VTE, DVT and PE after TKA were 1.09%, 0.63% and 0.27%.

However, we found that conventional use of tranexamic acid sequential preventive anticoagulation after perioperative treatments made the incidence of symptomatic VTE 3.33%, which was slightly higher than in the literature. Many clinical studies and several meta-analyses have confirmed that this way could effectively reduce the rates of blood loss and transfusion in TKA without increasing the risk of complications [6]. The distinction might be explained by the different diagnostic methods used, such as lower limb venography and lower extremity deep vein ultrasound, as well as the inconsistent observation time. The time with VTE risk is much longer than hospital stay, in Bin Abd Razak’s research [24]. The average hospital stay was 5.2 days, during which the specialist was consulted to determine whether VTE occurred. Follow-up observations were practiced by assessing the swelling of the body to determine VTE. In Januel’s research, the average length of follow-up was only 13 days. In this study, the average hospital stay was 18.4 days, and the observation time was even longer [25]. Also, symptomatic VTE was evaluated and diagnosed as comprehensive (independent of health care based on scoring system). With the Wells score for symptoms, the detection rate of VTE might increase.

Poeran et al. [26] conducted a retrospective study of 870,000 patients with complete hip/knee replacement for 6 consecutive years in 510 hospitals in the United States, finding that the incidence of deep venous thrombosis after using TXA was 0.4%, while the incidence was 0.5% in the group not using TXA. In addition, the majority of publications showed that TXA has an acceptable safety profile without increased risk of VTE [12, 27–31]. Our study found that compared with the historical control group, the incidence of symptomatic venous thrombosis did not increase significantly after using TXA. We believe that after using TXA, TKA in the conventional prevention of anticoagulation did not increase the risk of postoperative symptomatic VTE. Meanwhile, conventional routine lower limb vein imaging was not necessary for screening DVT.

The increase of Fbg was an independent risk factor, since Fbg was mainly involved in the coagulation process, and it has been reported as an independent risk factor for coronary heart disease [6]. The increase of plasma Fbg synthesis would lead to increased plasma Fbg levels, enhanced coagulation and formation of thrombosis [32]. In accord with these studies, our research showed a similar result that increased Fbg was significantly related to VTE. On the other hand, we found that BMI lower than 25 kg/m2 was a protective factor for symptomatic VTE, and several reports have also confirmed this finding [33, 34]. Moreover, extension of surgery, especially extension due to the bilateral TKA when compared with unilateral, was an independent risk factor for postoperative TKA [35]. Thus, prediction of VTE risk and stratification of patients was an important step in the future. There are several main aspects necessary to reduce the risk of symptomatic VTE in the case of TXA.

Firstly, according to the preoperative conventional color Doppler ultrasound screening of deep vein thrombosis, TXA should not be used in the operation if the patient had a positive result. Secondly, with postoperative Wells score, timely screening of asymptomatic deep vein thrombosis, as well as timely treatment should be paid attention to. Lastly, physical prevention and early functional exercise were necessary.

This research had several limitations, mainly because the patients in our study and in historical research underwent different methods in using TXA, and were treated with different surgeons. Moreover, the final judgment of symptomatic VTE was based on the doctor’s comprehensive consideration, and the judgments from different doctors would misguide the results. However, the VTE was judged according to the Wells score, so the study result was still reliable. Moreover, as the morbidity of symptomatic VTE was too low, its independent risk factor still needed a larger sample to analyze the result.

In conclusion, TXA appears to be a safe and efficacious medicine in TKA patients who are at high risk for VTE. Our study suggested that high BMI, low Fbg and bilateral simultaneous surgery might act as independent risk factors for VTE. For further safety evaluation, we need methods and procedures which are as uniform as possible in large-scale trials.

Conflict of interest

The authors declare no conflict of interest.

Table IV

Univariate analysis of preoperative laboratory and medication between venous thromboembolism (VTE) and non-VTE patients

Indicators	TXA				Placebo
	Symptomatic VTE	Non-VTE	χ2/t	P-value	Symptomatic VTE	Non-VTE	χ2/t	P-value
Number	24	696			39	1121
Pre-operative laboratory:
PT [s]	12.19 ±3.04	11.81 ±1.16	1.448	0.148	12.04 ±2.36	11.67 ±1.29	1.697	0.090
INR	1.09 ±0.27	1.04 ±0.42	0.841	0.409	1.14 ±0.33	1.09 ±0.25	1.213	0.225
APTT [s]	28.21 ±5.23	26.73 ±6.78	1.295	0.208	27.68 ±5.46	26.32 ±5.93	1.411	0.159
Fbg	2.73 ±0.70	3.05 ±0.70	0.196	0.046	2.83 ±0.67	3.09 ±0.81	1.981	0.048
Hgb [g/dl]	133.13 ±13.60	130.89 ±14.33	0.776	0.445	130.47 ±13.87	129.76 ±13.46	0.324	0.746
Hct (%)	39.59 ±3.72	38.95 ±4.96	0.670	0.503	38.80 ±4.08	37.97 ±3.95	1.289	0.198
Plt [per mm3]	209.96 ±61.31	217.84 ±60.67	0.625	0.532	205.73 ±64.59	212.64 ±66.67	0.637	0.524
D-dimer, n:
Normal	16	428	0.273	0.602	25	754	0.029	0.866
Abnormal	8	268			14	376
Premedication, n:
Aspirin	2	20	0.855	0.355	4	43	2.516	0.113
Lipid-lowering medicine	1	23	0.121	0.729	4	51	1.601	0.206

PT – prothrombin time, INR – international normalized ratio, APTT – activated partial thromboplastin time, Fbg – fibrinogen, Hgb – hemoglobin, Hct – hematocrit, Plt – platelets, TXA – tranexamic acid.

Table V

Univariate analysis of type and number of complications between venous thromboembolism (VTE) and non-VTE patients

Indicators	TXA				Placebo
	Symptomatic VTE	Non-VTE	χ2/t	P-value	Symptomatic VTE	Non-VTE	χ2/t	P-value
Number	24	696			39	1121
Type of complication*, n:
Hypertension	13	383	0.018	0.894	16	544	0.576	0.448
Diabetes	4	123	0.022	0.882	6	201	0.038	0.845
Cerebrovascular disease	5	66	2.216	0.137	5	188	0.187	0.665
Arrhythmia	1	23	0.119	0.729	1	42	0.002	0.963
Hyperlipidemia	2	22	0.656	0.418	1	47	0.009	0.926
History of malignancy	2	13	2.130	0.144	2	24	0.474	0.491
Anemia [g/l]:
< 120	5	123	0.016	0.899	7	221	0.005	0.946
≥ 120	19	573			32	900
Number of complications, n:
0–1	13	485	1.781	0.182	22	729	0.879	0.349
≥ 2	11	211			17	392

TXA – tranexamic acid.

Not all cases were included.